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Background/Aims: We aimed to evaluate the efﬁ  cacy and 
safety of peginterferon plus ribavirin for chronic hepatitis C 
(CHC) patients under real life setting in Korea. Methods: We 
retrospectively analyzed the medical records of 758 CHC 
patients treated with peginterferon plus ribavirin between 
2000 and 2008 from 14 university hospitals in the Gyeonggi-
Incheon area in Korea. Results: Hepatitis C virus (HCV) geno-
type 1 was detected in 61.2% of patients, while genotype 2 
was detected in 35.5%. Baseline HCV RNA level was ≥6×10
5 
IU/mL in 51.6% of patients. The sustained virological re-
sponse (SVR) rate was 59.6% regardless of genotype; 53.6% 
in genotype 1 and 71.4% in genotype 2/3. On multivariate 
analysis, male gender (p=0.011), early virological response 
(p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×10
5 IU/
mL (p=0.005) and adherence to the drug >80% of the 
planned dose (p<0.001) were associated with SVR. The rate 
of premature discontinuation was 35.7%. The main reason 
for withdrawal was intolerance to the drug due to common 
adverse events or cytopenia (48.2%). Conclusions: Our 
data suggest that the efﬁ  cacy of peginterferon and ribavirin 
therapy in Koreans is better in Koreans than in Caucasians 
for the treatment of CHC, corroborating previous studies that 
have shown the superior therapeutic efﬁ  cacy of this regimen 
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a leading cause 
of chronic liver disease worldwide.
1 Although the prevalence of 
anti-HCV has remained stable around 1% since 1991,
2 chronic 
hepatitis C (CHC) is the third most common etiology of chronic 
liver disease and hepatocellular carcinoma (HCC) in Korea.
3
After publication of three pivotal, randomized clinical trials,
4-6 
the combination of pegylated interferon alpha (peginterferon) 
and ribavirin is currently recommended as the standard of care 
for treatment of CHC.
1,7 Recent well-designed clinical trials dem-
onstrated variable rates of sustained virological response (SVR) 
between 39.8% and 66%, regardless of the genotype, and sug-
gested several predictive variables for successful treatment and 
rates of common adverse events.
8,9 However, the study subjects 
in clinical trials are usually highly selected individuals meeting 
complicated inclusion and exclusion criteria, so they may not 
reflect the general population of CHC patients encountered in Park SH, et al: Peginterferon Plus Ribavirin for Chronic Hepatitis C Patients  99
routine clinical practice.
1 Moreover, special attention may be 
given to the patients enrolled in clinical trials and this can be a 
factor influencing compliance or notification of adverse events.
There have been several Korean studies that evaluated the 
treatment efficacy of the peginterferon plus ribavirin regimen in 
CHC patients. These studies reported overall SVR rates of 63% to 
81%, a range that seems to be somewhat higher than in West-
ern countries.
10-13 However, because there are a smaller propor-
tion of CHC patients compared to chronic hepatitis B patients in 
Korea, it is difficult to perform a well-designed study to survey 
treatment efficacy for CHC in a single institution. Previous stud-
ies have limitations in that they were conducted in single insti-
tutions and do not have sufficiently large study populations to 
accurately reflect the Korean CHC population. 
K(G)yeonggi-Incheon Peginterferon Alpha and Ribavirin Ef-
fect in CHC Treatment (KIPECT) is a multicenter study group 
from 14 university hospitals in the Gyeonggi and Incheon areas 
(a large province and a city surrounding Seoul) in Korea. The 
aims of this study were to evaluate the efficacy and safety of 
peginterferon plus ribavirin for the treatment of Korean CHC 
patients in routine clinical practice and to confirm that the 
treatment efficacy of this regimen in Korean CHC patients is su-
perior to that reported in Western countries.
MATERIALS AND METHODS
1. Subjects
The study subjects were retrospectively included from 14 
large-volume university hospitals in Gyeonggi and Incheon. 
CHC patients 18 years or older with detectable serum HCV RNA 
and/or elevated serum alanine aminotransferase (ALT) levels 
for more than 6 months, who had been treated with peginter-
feron plus ribavirin from January 2000 to September 2008 were 
included. Exclusion criteria were acute hepatitis C, history of 
prior exposure to interferon or peginterferon, and no available 
data on HCV genotype. Patients with normal serum ALT levels, 
patients co-infected with human immunodeficiency virus (HIV) 
or hepatitis B virus (HBV), patients with chronic renal disease, 
and intravenous drug users were all included. Baseline clini-
cal and virologic characteristics were obtained by retrospective 
review of medical records, and when available, pre-treatment 
histologic data were also recorded. HCV RNA levels measured in 
copies/mL were converted into IU/mL using a conversion factor 
according to the particular assay used at each hospital.
1 Hepatic 
steatosis was categorized as present or absent, and the degree of 
hepatic fibrosis was classified as recommended by the Korean 
Study Group for the Pathology of Digestive Disease: grade 0, 
no fibrosis; grade 1, portal fibrosis; grade 2, periportal fibrosis; 
grade 3, septal fibrosis; and grade 4, cirrhosis.
14 Data collection 
was performed with an Excel-based case report form by physi-
cians at each individual hospital from April 2009 to August 
2009. The study protocol was approved by the Institutional Re-
view Boards at each hospital and was conducted in accordance 
with the principles of the Declaration of Helsinki.
2. Treatment of CHC
Patients were treated with either pegylated interferon alfa-2a 
or pegylated interferon alfa-2b plus ribavirin. The starting dos-
age and dose modification of peginterferon and ribavirin were 
determined based on the current guidelines suggested by the 
Korean Association for the Study of the Liver.
7 The duration of 
treatment was planned to be 24 weeks for genotype 2/3 and 48 
weeks for non-genotype 2/3.
7 However, according to the nature 
of this retrospective study, selection and discontinuation as well 
as dosing and treatment duration of peginterferon and ribavirin 
were not controlled, but reflected the clinical practice of the at-
tending physicians. 
3. Deﬁ  nition and evaluation of the treatment response
Virological responses during therapy were defined and evalu-
ated according to the current guidelines.
1,7 Quantitative HCV 
RNA values at baseline, 12 weeks after treatment, and at the 
end of treatment for HCV genotype 1/4 were recorded. The 
achievement of early virological response (EVR) was judged to 
be either complete (HCV RNA negative) or partial (more than 2 
log10 reduction in HCV RNA level compared to baseline) based 
on the HCV RNA level at 12 weeks. For CHC patients infected 
with genotype 2/3 HCV, quantitative HCV RNA levels at base-
line and at the end of treatment were recorded. Regardless of 
genotype, end-of-treatment response (ETR) was defined as HCV 
RNA negative status at the end of treatment. SVR was defined 
as HCV RNA negativity measured at 24 weeks after treatment 
cessation for all genotypes. HCV RNA negativity after 4 weeks 
of treatment was considered a rapid virological response (RVR), 
if tested. The same algorithm used for genotype 1/4 was applied 
in patients with genotype 5/6 HCV infection.
All analyses were made on an intention-to-treat basis.
4. Adverse events
Adverse events were categorized as flu-like symptoms, emo-
tional friability including depression or insomnia, alopecia, 
dermatologic reactions such as pruritis or rash, gastrointestinal 
disorders including nausea, vomiting, or diarrhea, and thyroid 
dysfunction. They were graded based on the severity: Grade I, 
mild symptoms that require no dose reduction; Grade II, dose 
reduction required due to an adverse event; Grade III, treat-
ment discontinuation due to an adverse event. The incidence 
of hematologic events in terms of serum absolute neutrophil 
count <500/mm
3, hemoglobin level <8.5 g/dL, or platelet count 
<25,000/mm
3 were recorded. Serious adverse events were de-
fined as death or problems requiring hospitalization. 
5. Statistical analysis
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dard deviations (SDs). Binary logistic regression analysis was 
employed to identify clinical and virological factors associated 
with treatment response, and categorical variables were com-
pared the chi-square test. All values were considered statistically 
significant when reaching a two-tailed p-value <0.05. Analyses 
were conducted using SPSS for Windows version 12.0 (SPSS 
Inc., Chicago, IL, USA). 
RESULTS
1. Baseline characteristics
A total of 758 CHC patients were included in the analysis. 
Detailed baseline demographics of the study subjects are pre-
sented in Table 1. Males comprised 60.2% of the sample, and 
the mean age was 50.2±12.0 years. Based on a cut-off body 
mass index of 25 kg/m
2, 37.4% of the patients were classified as 
obese, and 14.1% of subjects had a history of diabetes mellitus. 
Eighty patients (10.6%) had a history of transfusion and 38 (5%) 
patients had a history of intravenous drug use. Eighteen patients 
(2.4%) were also positive for hepatitis B surface antigen and 6 
patients (0.8%) were co-infected with HIV. Peginterferon alfa-
2a was used in 61.9% of patients and peginterferon alfa-2b was 
used in 38.1%. HCV genotype 1 was the most common (61.2%) 
and genotype 2 was the second most common (35.5%). Geno-
type 1b, genotype 2a/c, genotype 2 of unclassified subtype, and 
genotype 1a constituted 54.1%, 26.5%, 4%, and 4% of patients, 
respectively. The mean HCV RNA level was 3.2±11.63×10
6 IU/
mL and 51.6% had a high viral load when classified according 
to a cut-off value of 6×10
5 IU/mL. Histologic data on the degree 
of hepatic fibrosis was available for 244 subjects and 11.1% 
of them had cirrhosis. Histologic data on hepatic steatosis was 
available for 229 subjects, and steatosis was present in 30.2% of 
them. 
2. Treatment efﬁ  cacy
Regardless of the genotype, the overall SVR rate was 59.6%, 
and the rates of EVR and ETR were 69.1% and 73.5%, respec-
tively (Fig. 1). SVR rate was compared according to various 
baseline factors (Fig. 2A-E) and on-treatment factors (Fig. 2F-
G). The SVR rate of genotype 2/3 was higher than that of geno-
type 1/4 (71.4% vs 53.6%, p<0.001; Fig. 2A). When compared 
according to the baseline RNA level, patients with a low viral 
load (HCV RNA <6×10
5 IU/mL) had a higher SVR rate than 
those with a high viral load (65.4% vs 55.5%, p<0.001; Fig. 
2B). Male patients had a higher SVR rate than females (63.8% 
vs 53.3%, p=0.004; Fig. 2C) and patients <40 years old had a 
higher SVR rate than patients ≥40 years old (69.2% vs 56.3%, 
p=0.001; Fig. 2D). SVR rate was also compared according to the 
grade of hepatic fibrosis in 244 subjects with available data. The 
patients with low grade (grade 0 to 2) fibrosis had a higher SVR 
rate than those with high grade (grade 3 to 4) fibrosis (68.2% vs 
45.7%, p=0.004; Fig. 2E). There was no significant difference in 
SVR rate according to obesity, history of diabetes mellitus, base-
line ALT levels, type of peginterferon, or presence of hepatic ste-
atosis on histology. The patients with EVR (partial or complete) 
had a higher SVR rate than those without (73.1% vs 29.5%, 
p<0.001; Fig. 2F). Adherence to the drug regimen, defined as 
a cumulative drug dose greater than 80% of the planned dose, 
was associated with a higher SVR rate (78% vs 26.8%, p<0.001; 
Fig. 2G).
Table 1. Baseline Characteristics of the Study Subjects (n=758)
Characteristic Value
Gender, M/F 456/302 (60.2/39.8)
Age* 50.2±12.0
  ≥40 yr 560 (73.9)
Body mass index ≥25 kg/mm
2 226 (37.4)
History of diabetes mellitus 107 (14.1)
History of intravenous drug use 38 (5.0)
History of transfusion 80 (10.6)
Hepatitis B surface antigen positivity 18 (2.4)
Human immunodeficiency virus infection 6 (0.8)
Pegylated interferon alfa-2a/2b 469 (61.9)/289 (38.1)
Alanine aminotransferase, U/L 98.2±85.0
Hepatitis C virus genotype
  1/2/3/4/5,6 461 (61.2)/
268 (35.5)/15 (1.9)/
1 (0.2)/9 (1.2)
Hepatitis C virus RNA, ×10
6 IU/mL     3.2±11.63
  ≥6×10
5 IU/mL 391 (51.6)
Fibrosis  Available data in 
244 subjects
  Grade 0/1/2/3/4 17 (7)/49 (20.2)/
108 (44)/43 (17.7)/
27 (11.1)
Steatosis Available data in 
229 subjects
  Present 60 (30.2)
*Data are presented as mean±SD or number (%).
Fig. 1. Overall treatment response irrespective of hepatitis C virus 
genotype. The rates of early virological response (EVR), end-of-treat-
ment response (ETR), and sustained virological response (SVR) were 
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3. Factors associated with SVR
To identify predictors of SVR, univariate and multivariate 
analysis was performed using a binary logistic regression model 
(Table 2). Male gender, age <40 years, genotype 2/3, low base-
line viral load, achievement of EVR, and cumulative drug dose 
≥80% of the planned dose were all statistically significant on 
univariate analysis and were therefore included in the multivari-
ate model. On multivariate analysis, cumulative drug dose ≥80% 
of the planned dose (odds ratio [OR], 5.858; 95% confidence 
interval [CI], 3.961 to 8.664; p<0.001), achievement of EVR (OR, 
5.297; 95% CI, 3.409 to 8.230; p<0.001), HCV genotype 2/3 
(OR, 2.554; 95% CI, 1.673 to 3.899; p<0.001), HCV RNA <6×10
5 
IU/mL (OR, 1.736; 95% CI, 1.176 to 2.561; p=0.005), and male 
gender (OR, 1.645; 95% CI, 1.123 to 2.410; p=0.011) were all 
associated with SVR.
Fig. 2. Comparison of sustained virological response (SVR) rates accord-
ing to baseline characteristics and on-treatment factors. The SVR rates 
were significantly better in chronic hepatitis C patients infected with 
genotype 2/3 (A), low pre-treatment viral load (B), male gender (C), age 
less than 40 years (D), and less advanced fibrosis on histology (E). During 
treatment, achievement of early virological response (EVR) (F) and ad-
herence (a cumulative drug dose greater than 80% of the planned dose) (G) 
were associated with better SVR rate.102  Gut and Liver, Vol. 6, No. 1, January 2012
4. Adverse events
Four hundred eighty-seven subjects (64.2%) experienced one 
or more common adverse events (Table 3). Flu-like symptoms 
were the most common adverse event and occurred in 31.9% 
of patients. Gastrointestinal disorders occurred in 25.3% and 
dermatologic reactions were observed in 24.5%. Emotional fri-
ability developed in 17.4% and alopecia occurred in 11.9% of 
the patients. Four cases of thyroid dysfunction after treatment 
occurred, all of which presented as hyperthyroidism. One patient 
complained of tremor and one case of third cranial nerve palsy 
was observed during the treatment period. As shown in Table 
3, most of the common adverse events were grade 1 in severity, 
however, some led to the discontinuation of treatment. Cyto-
penia during the treatment period was also noted. Neutropenia 
with an absolute neutrophil count <500/mm
3, anemia based on 
serum hemoglobin <8.5 g/dL, and thrombocytopenia according 
to a platelet count <25,000/mm
3 occurred in 4.5%, 6.6%, and 
0.8% of patients, respectively. Two deaths occurred during the 
treatment period; one was an unexpected sudden death and the 
other was caused by severe sepsis secondary to neutropenia. 
Invasive infections developed in 4 subjects, which included 2 
cases of urinary tract infection leading to sepsis, one case of tu-
berculosis peritonitis, and one case of severe sepsis originating 
from acute gastroenteritis. Eight adverse events were considered 
treatment-related serious adverse events, including invasive in-
fections and cases of cytopenia requiring hospital admission. 
5. Discontinuation of peginterferon plus ribavirin
Premature discontinuation of peginterferon plus ribavirin 
occurred in 35.7% (271 subjects) of all patients. When the 271 
cases were classified according to the cause of discontinuation, 
intolerance to the treatment drug (common adverse events or 
cytopenia) was the most common (48.2%) and loss to follow-
up was the second (26.5%). Fifty-one patients (18.8%) requested 
to stop treatment due to economic problems, and treatment was 
terminated in 20 patients (2.7%) due to the lack of a virologic 
response. 
6. Additional analysis of RVR
Because the concept of RVR appeared relatively recently, 
only 193 patients (25.5%) had available data on RVR. Subgroup 
Table 2. Univariate and Multivariate Analysis of Factors Associated with Sustained Virological Response
Factor
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Male vs Female 1.545 (1.149-2.007) 0.004 1.645 (1.123-2.410) 0.011
Age <40 yr vs ≥40 yr 1.747 (1.237-2.466) 0.002 1.480 (0.957-2.290) 0.078
HCV genotype 2/3 vs non 2/3   2.008 (1.473-2.738) <0.001 2.554 (1.673-3.899) <0.001
HCV RNA <6×10
5 IU/mL vs ≥6×10
5 IU/mL 1.513 (1.111-2.060) 0.009 1.736 (1.176-2.561) 0.005
Drug adherence ≥80% vs <80% 9.656 (6.849-13.613) <0.001 5.858 (3.961-8.664) <0.001
EVR yes vs no 6.496 (4.619-9.134) <0.001 5.297 (3.409-8.230) <0.001
OR, odds ratio; CI, confidence interval; HCV, hepatitis C virus; EVR, early virological response.
Table 3. Summary of Adverse Events
Event Incidence, No. (%)
Overall 487 (64.2)
Death 2 (0.26)
Common adverse events Overall Grade 1 Grade 2 Grade 3
   Flu-like symptoms 242 (31.9) 183 (24.1) 29 (3.8) 30 (4.0)
   Gastrointestinal disorder 192 (25.3) 135 (17.8) 34 (4.5) 23 (3)
   Dermatologic reaction 186 (24.5) 153 (20.2) 21 (2.8) 12 (1.5)
   Emotional friability 132 (17.4) 98 (12.9) 13 (1.7) 21 (2.8)
   Alopecia 90 (11.9) 83 (10.9) 5 (0.7) 2 (0.3)
Hematologic events
   ANC <500/mm
3 34 (4.5)
   Hemoglobin <8.5 g/dL 50 (6.6)
   Platelet <25,000/mm
3 6 (0.8)
ANC, absolute neutrophil count.Park SH, et al: Peginterferon Plus Ribavirin for Chronic Hepatitis C Patients  103
analysis was performed with these patients. This subgroup 
showed male predominance (55.4%), and 72.5% of patients in 
this group were 40 years old or older. One hundred eighteen 
(61.1%) had HCV genotype 1/4 and 52.8% of the patients had 
HCV RNA level ≥6×10
5 IU/mL. The overall RVR rate in these 
191 subjects was 57% regardless of the genotype; 51.7% in 
patients infected with genotype 1/4 and 65.3% in patients with 
genotype 2/3. The patients with RVR had a significantly higher 
SVR than those without (77.3% vs 36.1%; OR, 6.007; 95% CI, 
3.193 to 11.300; p<0.001) irrespective of genotype (Fig. 3A). 
When analyzed by genotype, the achievement of RVR was as-
sociated with SVR both in genotype 1/4 (67.2% vs 33.3%; OR, 
4.100; 95% CI, 1.903 to 8.833; p<0.001; Fig. 3B) and genotype 
2/3 (89.8% vs 42.3%; OR, 12.000; 95% CI, 3.582 to 40.189; 
p<0.001; Fig. 3C). 
DISCUSSION
In Korea, chronic HCV infection is one of the leading causes 
of chronic liver disease and HCC. In one study, 11% of 823 cas-
es of liver cirrhosis were ascribed to HCV infection.
15 Although 
HBV infection is still the most common cause of chronic liver 
disease and HCC, the overall prevalence of HBsAg positivity has 
decreased as a result of the nationwide vaccination program.
16 
However, according to the online disease statistics database 
of the Korean Centers for Disease Control and Prevention, the 
number of reported cases of CHC have increased annually. In 
2003, 2,033 cases of CHC were reported, and this number had 
increased to 4,401 in 2006 and 6,406 in 2009.
17
Studies of the natural history of CHC provide justification for 
the treatment of chronic HCV infection as up to 80% of individ-
uals infected with HCV will remain chronically infected, and the 
risk of developing liver cirrhosis in these patients ranges from 5% 
to 25% over periods of 25 to 30 years.
18,19 Patients with HCV-
related liver cirrhosis are at risk for the development of hepatic 
decompensation (30% over 10 years) as well as HCC (1% to 3% 
per year).
20 Even though several management modalities such as 
endoscopic variceal ligation or surveillance programs for early 
detection of HCC have been developed, a remarkable improve-
ment in long-term survival has not been observed. Thus, more 
efficient management strategies specific to the etiologic agent 
are required to improve survival.
15 In one retrospective study 
including 2,145 CHC patients with a median follow-up period 
of 55 months, achieving SVR was associated with halted disease 
progression in patients with CHC. The hazard ratio for disease 
progression was 3.1 for patients without SVR compared to those 
with SVR.
21 The results of this study explain why active ap-
plication of antiviral therapy and efforts to improve treatment 
efficacy in CHC patients are required.
The treatment of CHC has evolved significantly in the past 
two decades in an attempt to stop viral replication and disease 
progression.
22 The combination of peginterferon and ribavirin, 
which is the current standard of care for CHC, requires less fre-
quent injection due to a prolonged half-life and resulted in im-
proved SVR rates around 55% in several clinical trials.
1 Howev-
er, patients infected with genotype 1 HCV still show lower SVR 
rates, and adverse events and intolerance to the combination 
therapy remain a concern. Recent trials have achieved improved 
Fig. 3. The association between rapid virological response (RVR) and sus-
tained virological response (SVR) was analyzed in 193 patients. The pa-
tients who showed RVR had significantly higher rates of SVR than those 
who did not, irrespective of genotype (A). When analyzed according to 
hepatitis C genotype, the association between RVR and SVR remained 
significant in genotype 1 (B) and genotype 2/3 (C).104  Gut and Liver, Vol. 6, No. 1, January 2012
SVR rates of 61% to 68% and 67% to 75% in patients with HCV 
genotype 1 infection by combining new HCV-specific protease 
inhibitors, telaprevir or boceprevir.
22 Although these new drugs 
look promising, they seems to be added to peginterferon plus 
ribavirin therapy, and the role of peginterferon plus ribavirin 
combination therapy is expected to last. Thus, a treatment strat-
egy to improve treatment outcome and reduce adverse events is 
required. In this regard, pretreatment predictors of response are 
useful for estimating the likelihood of SVR, in identifying opti-
mal candidates, and advising patients. 
The treatment efficacy of peginterferon plus ribavirin combi-
nation therapy varies among different HCV genotypes. Several 
well-designed and controlled clinical trials reported SVR rates 
of 32% to 40.9% in genotype 1 and 65% to 96% in genotype 
2/3.
8,9,23 A retrospective multicenter study in the setting of rou-
tine clinical practice performed in the United States reported 
somewhat worse treatment outcomes; SVR rates of 20% in 
genotype 1, 52% in genotype 2, and 43% in genotype 3.
24 An 
ethnic difference in treatment response to peginterferon plus 
ribavirin therapy has been suggested. One retrospective study of 
patients with CHC treated at 23 German gastroenterology prac-
tices in a routine clinical setting revealed a SVR rate of 46.5% 
in genotype 1- and 77.3% in genotype 2/3-infected patients.
25 It 
has been suggested that Asian CHC patients are more likely to 
have SVR than Caucasians.
26 In accordance with these findings, 
Korean CHC patients seem to have better treatment outcomes, 
with SVR rates of 46% to 70% in genotype 1 infection and 76% 
to 94% in genotype 2/3 infection.
10-13,27-30 Treatment outcome 
from Korean population is summarized in Table 4 (data from 
only published article was included). 
Although several studies of peginterferon plus ribavirin treat-
ment have been conducted in Korean CHC patients, the data 
are still not sufficient to develop guidelines specific to Koreans. 
Thus, we and the KIPECT study group determined that a large 
confirmatory study was needed. The SVR rate in this study was 
59.6% in all patients regardless of genotype, 53.6% in genotype 
1/4, and 71.5% in genotype 2/3. These response rates are higher 
than those reported in Western CHC patients, and our findings 
provide evidence of better treatment outcome in Korean pa-
tients. The mechanism underlying the superior response rate in 
Asian patients remained unclear until recently. Recent studies 
have suggested that a genetic polymorphism might account for 
the ethnic differences in response rates. These studies reported 
a higher frequency of favorable interleukin 28B alleles in Asian 
patients with CHC, which may be a reason for better treatment 
outcomes observed in Asian CHC patients.
31-33 A high frequency 
of favorable alleles and their association with SVR was also 
found in 118 Korean patients with CHC. The frequencies of ma-
jor homozygotes (TT), heterozygotes (GT), and minor homozy-
gotes (GG) of rs8099917 were 85%, 14%, and 1%, respectively.
34 
Of the 55 patients with HCV genotype 1 infection in that study, 
the SVR rate was 67% and 44% for the major allele and minor 
or hetero allele, respectively. 
Prediction of SVR during treatment would allow clinicians to 
identify patients most likely to benefit from therapy. The viral 
genotype and pretreatment viral load have been consistently 
regarded as two major predictors of SVR. SVR rates were higher 
in patients infected with non-genotype 1 HCV and in those 
with a viral load less than 6×10
5 IU/mL. Other less consistently 
reported baseline characteristics associated with a favorable 
response include the dose of peginterferon and ribavirin, female 
gender, age younger than 40 years, non-African-American race, 
lower body weight, the absence of insulin resistance, elevated 
ALT levels, and the absence of advanced fibrosis on liver bi-
opsy.
8,9,23 In terms of viral kinetics, RVR
35-37 and EVR
5,38 are also 
helpful in predicting treatment response. Baseline HCV RNA 
level, HCV genotype, and liver cirrhosis also have been docu-
mented as predictors of treatment response in studies of Koran 
patients (Table 4). In this study, pretreatment baseline charac-
teristics of HCV genotype 2/3 and low viral load (HCV RNA less 
than 6×10
5 IU/mL) were significant predictors of SVR and these 
findings were consistent with previous results. However, our 
finding that males had a higher SVR rate than females is some-
what different from other studies, but no other studies of Korean 
Table 4. Summary of Previous Studies on the Treatment of Chronic Hepatitis C with Peginterferon Plus Ribavirin in Korea
Reference No. 10 27 11 28 12 13
No. of patients
  (genotype 1,4/2,3)
75
(29/46)
42
(0/42)
84
(35/49)
86
(59/27)
141
(59/82)
314
(139/175)
SVR, overall, % 71 63 81 73-80
SVR in G1/4, % 55 46 68 70 63-67
SVR in G2/3, % 86 90 76 94 89 79-91
Predictors of SVR Baseline HCV RNA
HCV genotype
Baseline HCV RNA
HCV genotype
BMI >28 kg/m
2
Liver cirrhosis
HCV genotype
Liver cirrhosis
EVR
Baseline HCV RNA
HCV genotype
AST
Low APRI score
SVR, sustained virological response; G1/4, genotype 1/4; G2/3, genotype 2/3; HCV, hepatitis C virus; BMI, body mass index; EVR, early virologi-
cal response; AST, aspartate aminotransferase; APRI, aspartate aminotransferase platelet ratio index.Park SH, et al: Peginterferon Plus Ribavirin for Chronic Hepatitis C Patients  105
patients with HCV infection have identified female gender as a 
predictor of SVR. Whether a difference in treatment efficacy of 
peginterferon plus ribavirin therapy between males and females 
actually exists is uncertain. 
The achievement of EVR during treatment was strongly as-
sociated with SVR (OR, 5.297; p<0.001) in this study. Because 
many of the study subjects had been treated before the concept 
of RVR appeared, HCV RNA at 4 weeks after treatment was 
tested in only 193 patients (25.5%). When the analysis was 
performed in these subjects, the achievement of RVR was sig-
nificantly associated with SVR in all patients (77.3% vs 36.1%, 
p<0.001) as well as in patients infected with genotype 1 HCV 
(67.2% vs 33.3%, p<0.001) and genotype 2/3 (89.8% vs 42.3%, 
p<0.001). However, because these results are based on univari-
ate analysis, they require confirmation on multivariate analysis 
including other baseline clinical characteristics. 
Treatment with peginterferon and ribavirin therapy was as-
sociated with many adverse events. In this study, 64.2% of sub-
jects experienced at least one or more adverse events. As report-
ed in other studies, flu-like symptoms were the most common 
(31.9%), and gastrointestinal symptoms and skin reactions were 
the second (25.3%) and the third (24.5%) most common. Most 
adverse reactions were mild in severity and easily manage-
able. However, 88 patients (11.6%) discontinued treatment due 
to common adverse events. Given that drug adherence ≥80% 
of the planned dose had the strongest association (OR, 5.858; 
95% CI, 3.409 to 8.230; p<0.001) with SVR in this study, care-
ful and thoughtful management of common adverse events and 
encouragement of patients to adhere to their treatment regimen 
are critical. 
Our KIPECT study is the first and largest multicenter study 
to evaluate the efficacy and tolerability of peginterferon plus 
ribavirin therapy for the treatment of CHC patients in routine 
clinical practice in Korea. As reported in other studies, SVR rates 
in Korean CHC patients were higher than that in Western CHC 
patients. Other findings including predictors of SVR, adverse 
events, and discontinuation were not different from those re-
ported in other studies. 
Our study is limited due to its retrospective and observational 
design; however, our findings are meaningful in that they re-
flect the current clinical practices in Korea. The fact that RVR 
was only available in some patients is a shortcoming of this 
study, and conclusions regarding the possibility of shortening 
the treatment period cannot be made. In order to create a treat-
ment strategy tailored to Korean CHC patients, further research 
should focus on RVR in CHC as well as the influence of genetic 
polymorphisms of interleukin 28B on treatment outcome. The 
KIPECT study is a representative study of CHC treatment in 
Korea, and we expect that our findings will be helpful building 
informing revised guidelines for the treatment of CHC in Korea.
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